دورية أكاديمية
Kam ir kada gali būti naudingas kairiojo prieširdžio ausytės uždarymas ; Indications for the left atrial apendage closure procedure
| العنوان: | Kam ir kada gali būti naudingas kairiojo prieširdžio ausytės uždarymas ; Indications for the left atrial apendage closure procedure |
|---|---|
| المؤلفون: | Pranevičius, Robertas, Morkūnaitė, Kristina, Unikas, Ramūnas |
| المصدر: | Lietuvos bendrosios praktikos gydytojas, Kaunas : Vitae Litera, 2020, t. 24, Nr. 1, p. 27-33 ; ISSN 1392-3218 |
| سنة النشر: | 2020 |
| المجموعة: | LSRC VL (Lithuanian Social Research Centre Virtual Library) / LSTC VB (Lietuvos socialinių tyrimų centras virtualią biblioteką) |
| مصطلحات موضوعية: | Atrial fibrillation, drug therapy, surgery, Anticoagulants, therapeutic use, adverse effects, Hemorrhage, chemically induced, Stroke, prevention&control, Warfarin, administration&dosage, Adninistration, oral, Atrial appendage, info:eu-repo/classification/udc/616.12-008.313.2 |
| الوصف: | Atrial fibrillation (PV) remains the most common arrhythmia that is encountered in clinical practice. Patients with this arrhythmia have a significantly higher rate of stroke, which is why they are usually prescribed vitamin K antagonists (warfarin) or direct oral anticoagulants (DOACs). To date, patients with severe conditions who have co-pathologies or a history of bleeding, being unable to take warfarin resulting in reduced doses of DOACs, it has become increasingly difficult to balance the therapeutic benefit with the lowest risk of new complications for the patient. The alternative for these patients is left atrial appendage (LAA) closure, which was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alternative to warfarin, for patients with nonvalvular atrial fibrillation. Since recently there was no clinical indication for LAA closure of patient, complications and delayed outcome after closure implantation were not clearly defined and evaluated. After a series of clinical trials (PREVAIL, PROTECT-AF) particularly LAA closure as therapy is introduced as a safe general clinical practice. Clinical results showed that the procedure with Watchman occluder device provides stroke prevention in nonvalvular atrial fibrillation comparable to warfarin, with additional reductions in major bleeding, particularly hemorrhagic stroke, and mortality. Moreover, the LAA closure group results have shown reduced risk of stroke, decreased bleeding and risk of death. Considering the world-wide practice first successful procedure in the Hospital of Lithuanian University of Health Sciences Kauno klinikos was performed. Conclusion. Based on global post-FDA approval clinical experience of LAA closure, procedural success was high and complication rates were low. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | Lithuanian English |
| العلاقة: | http://lsmu.lvb.lt/LSMU:ELABAPDB49037619&prefLang=en_USTest |
| الإتاحة: | http://lsmu.lvb.lt/LSMU:ELABAPDB49037619&prefLang=en_USTest |
| رقم الانضمام: | edsbas.D5E686B5 |
| قاعدة البيانات: | BASE |
| الوصف غير متاح. |